Antioxidants in Down Syndrome: From Preclinical Studies to Clinical Trials

There is currently no effective pharmacological therapy to improve the cognitive dysfunction of individuals with Down syndrome (DS). Due to the overexpression of several chromosome 21 genes, cellular and systemic oxidative stress (OS) is one of the most important neuropathological processes that con...

Descripción completa

Detalles Bibliográficos
Autores principales: Rueda Revilla, Noemí, Martínez-Cué, Carmen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7464577/
https://www.ncbi.nlm.nih.gov/pubmed/32756318
http://dx.doi.org/10.3390/antiox9080692

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7464577/
https://www.ncbi.nlm.nih.gov/pubmed/32756318
http://dx.doi.org/10.3390/antiox9080692

Ejemplares similares